These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 22970727)

  • 1. Demand for pneumococcal vaccination under subsidy program for the elderly in Japan.
    Kondo M; Yamamura M; Hoshi SL; Okubo I
    BMC Health Serv Res; 2012 Sep; 12():313. PubMed ID: 22970727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does subsidy work? Price elasticity of demand for influenza vaccination among the elderly in Japan.
    Kondo M; Hoshi SL; Okubo I
    Health Policy; 2009 Aug; 91(3):269-76. PubMed ID: 19185945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pricing and uptake rate of public funded pneumococcal vaccination for the elderly in Japan].
    Hoshi SL; Kondo M; Okubo I
    Nihon Koshu Eisei Zasshi; 2010 Jul; 57(7):505-13. PubMed ID: 20845712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between public subsidies and vaccination rates with the 23-valent pneumococcal vaccine in elderly persons, including the influence of the free vaccination campaign after the Great East Japan Earthquake.
    Naito T; Matsuda N; Tanei M; Watanabe Y; Watanabe A
    J Infect Chemother; 2014 Jul; 20(7):450-3. PubMed ID: 24767466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic Evaluation of Immunisation Programme of 23-Valent Pneumococcal Polysaccharide Vaccine and the Inclusion of 13-Valent Pneumococcal Conjugate Vaccine in the List for Single-Dose Subsidy to the Elderly in Japan.
    Hoshi SL; Kondo M; Okubo I
    PLoS One; 2015; 10(10):e0139140. PubMed ID: 26444287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Study on pricing and uptake rate of influenza vaccination for the elderly in Japan with a simple random sampling method].
    Hoshi SL; Kondo M; Okubo I
    Nihon Koshu Eisei Zasshi; 2008 Jan; 55(1):19-29. PubMed ID: 18318267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The estimated impact of the 5-year national vaccination program on the trend of 23-valent pneumococcal polysaccharide vaccine vaccination rates in the elderly in Japan, 2009-2018.
    Naito T; Suzuki M; Fujibayashi K; Kanazawa A; Takahashi H; Yokokawa H; Watanabe A
    J Infect Chemother; 2020 Apr; 26(4):407-410. PubMed ID: 31924523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of influenza vaccine subsidies for older adults on vaccination coverage and mortality before and during the COVID-19 pandemic: an ecological study in Japan.
    Ando T; Ibuka Y; Goto R; Haruta J; Le DD; Fujishima S
    Public Health; 2023 Nov; 224():152-158. PubMed ID: 37797561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors associated with PPSV23 coverage among older adults in Japan: a nationwide community-based survey.
    Murakami Y; Kanazu S; Petigara T; Oba MS; Nishiwaki Y; Watanabe A
    BMJ Open; 2019 Jul; 9(7):e030197. PubMed ID: 31315877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of the national routine vaccination program on 23-valent pneumococcal polysaccharide vaccine vaccination rates in elderly persons in Japan.
    Naito T; Yokokawa H; Watanabe A
    J Infect Chemother; 2018 Jun; 24(6):496-498. PubMed ID: 29398479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with pneumococcal vaccination in elderly people: a cross-sectional study among elderly club members in Miyakonojo City, Japan.
    Sakamoto A; Chanyasanha C; Sujirarat D; Matsumoto N; Nakazato M
    BMC Public Health; 2018 Oct; 18(1):1172. PubMed ID: 30314498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful introduction of an underutilized elderly pneumococcal vaccine in a national immunization program by integrating the pre-existing public health infrastructure.
    Yang TU; Kim E; Park YJ; Kim D; Kwon YH; Shin JK; Park O
    Vaccine; 2016 Mar; 34(13):1623-1629. PubMed ID: 26850759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact on vaccination coverage following introduction of a routine pneumococcal vaccination programme for the elderly in Japan.
    Shono A; Hoshi SL; Kondo M
    Vaccine; 2018 Sep; 36(39):5886-5890. PubMed ID: 30143271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
    Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
    Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do Pneumococcal Conjugate Vaccines Represent Good Value for Money in a Lower-Middle Income Country? A Cost-Utility Analysis in the Philippines.
    Haasis MA; Ceria JA; Kulpeng W; Teerawattananon Y; Alejandria M
    PLoS One; 2015; 10(7):e0131156. PubMed ID: 26131961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pneumococcal pneumonia and influenza vaccination quality improvement program for women receiving chemotherapy for gynecologic cancers at a major tertiary cancer Centre.
    McGinnis JM; Jones R; Hillis C; Kokus H; Thomas H; Thomas J; Alyafi M; Bernard L; Eiriksson LR; Elit LM; Hirte H; Jimenez W; Reade CJ; Kumar Tyagi N; Helpman L
    Gynecol Oncol; 2021 Apr; 161(1):236-243. PubMed ID: 33526258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling Possible Inclusion of Pneumococcal Conjugate Vaccine into the National Immunization Program for Infants in India.
    Ghia C; Wasserman M; Fletcher M; Farkouh R; Rambhad G
    Value Health Reg Issues; 2018 May; 15():99-105. PubMed ID: 29655052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influenza and pneumococcal vaccine distribution and use in primary care and hospital settings in Scotland: coverage, practice and policies.
    Kyaw MH; Wayne B; Chalmers J; Jones IG; Campbell H
    Epidemiol Infect; 2002 Jun; 128(3):445-55. PubMed ID: 12113489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
    Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
    Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The composition of demand for newly launched vaccines: results from the pneumococcal and rotavirus vaccine introductions in Ethiopia and Malawi.
    Williams BA; Kidane T; Chirwa G; Tesfaye N; Prescott MR; Scotney ST; Valle M; Abebe S; Tambuli A; Malewezi B; Mohammed T; Kobayashi E; Wootton E; Wong R; Dosani R; Subramaniam H; Joseph J; Yavuz E; Apple A; Le Tallec Y; Kang'ethe A
    Health Policy Plan; 2016 Jun; 31(5):563-72. PubMed ID: 26856361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.